Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.
Hans Lee, MD, assistant professor, director, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.
An increasing number of options have become available for the treatment of patients with relapsed/refractory multiple myeloma, Lee says. Although many of these regimens are reserved for patients with early relapses, more therapies are emerging for use in heavily pretreated patients who experience late relapses, Lee explains.
Additional options allow for tailored treatment selection based on multiple factors, Lee says. Disease characteristics and treatment characteristics, such as known adverse effects associated with a particular regimen, should be considered, Lee explains. Additionally, patient characteristics, such as comorbidities, age, and preference, are important factors to consider during the treatment selection process, Lee concludes.